Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.

These markers indicate stress or strain on the heart muscle:

Natriuretic Peptides (BNP)

Cardiac myocytes produce these hormones in response to ventricular stretching and pressure overload. They are primarily used to diagnose heart failure, distinguish it from other causes of dyspnea, and monitor the response to therapy. Elevated levels of these peptides correlate with the severity of heart failure and tend to be higher in women and those with renal insufficiency. Prompt measurement of BNP in acute conditions aids in rapid diagnosis and effective treatment planning. The half-life of BNP is approximately 20 minutes.

These markers provide information about inflammation and can predict cardiovascular events:

C-reactive protein (CRP)

The liver produces CRP in response to inflammation, mainly due to infections or chronic inflammatory conditions. Elevated CRP levels are linked with an increased risk of atherosclerosis and cardiovascular events, for instance, myocardial infarction and stroke. CRP levels can rise within 4-6 hours after the onset of inflammation or tissue injury, with peak levels typically observed around 24-48 hours. Measuring CRP levels can help identify patients at higher risk of future cardiovascular events, thereby guiding preventive measures and interventions. CRP links inflammation and cardiovascular diseases, highlighting the importance of managing systemic inflammation to improve cardiovascular outcomes.

Homocysteine (Hcy)

Homocysteine is an amino acid generated during the breakdown of proteins. High concentrations of homocysteine are associated with a greater risk of heart-related illnesses, including coronary artery disease and stroke. High levels of homocysteine can damage the endothelial lining of blood vessels, promoting atherosclerosis and thrombosis. Assessing homocysteine levels is particularly important in patients with a family history of early cardiovascular disease, as it can guide early interventions to reduce cardiovascular risk. Based on dietary intake, genetic factors, and renal function, homocysteine levels can fluctuate.